P110-γand -δact in lymphocytes chemotaxis, presenting distinct, nonredundant roles in B- and T-cell migration and adhesion to stromal cells. Moreover, phosphoinositide-3-kinase-γinhibition contributes to regulate macrophage polarization inhibiting cancer growth. Duvelisib (IPI-145) is an oral first-in-class, dual phosphoinositide-3-kinase inhibitor targeting p110-/γexerting its activity in preclinical studies across different prognostic groups. In a large Phase III study, duvelisib showed superior progression-free survival and overall response rate compared with ofatumumab, thus leading to its approval for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Immune-related effects are the main reason for treatment suspension, thus affecting survival benefit. Nevertheless, the correct management of adverse events, eventually including dose modification, allows patients to remain on treatment. In conclusion, duvelisib represents a promising treatment in chronic lymphocytic leukemia and a salvage therapy after ibrutinib.

Anna, M., Alessandra, T., Marina, D., Giulia, Z., Cairoli, R., Marco, M. (2019). Duvelisib: A new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia. FUTURE ONCOLOGY, 15(19), 2227-2239 [10.2217/fon-2018-0881].

Duvelisib: A new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia

Cairoli Roberto;
2019

Abstract

P110-γand -δact in lymphocytes chemotaxis, presenting distinct, nonredundant roles in B- and T-cell migration and adhesion to stromal cells. Moreover, phosphoinositide-3-kinase-γinhibition contributes to regulate macrophage polarization inhibiting cancer growth. Duvelisib (IPI-145) is an oral first-in-class, dual phosphoinositide-3-kinase inhibitor targeting p110-/γexerting its activity in preclinical studies across different prognostic groups. In a large Phase III study, duvelisib showed superior progression-free survival and overall response rate compared with ofatumumab, thus leading to its approval for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Immune-related effects are the main reason for treatment suspension, thus affecting survival benefit. Nevertheless, the correct management of adverse events, eventually including dose modification, allows patients to remain on treatment. In conclusion, duvelisib represents a promising treatment in chronic lymphocytic leukemia and a salvage therapy after ibrutinib.
Articolo in rivista - Articolo scientifico
chronic lymphocytic leukemia; CLL; dual inhibition; duvelisib; novel agents; PI3K; SLL;
English
2019
15
19
2227
2239
reserved
Anna, M., Alessandra, T., Marina, D., Giulia, Z., Cairoli, R., Marco, M. (2019). Duvelisib: A new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia. FUTURE ONCOLOGY, 15(19), 2227-2239 [10.2217/fon-2018-0881].
File in questo prodotto:
File Dimensione Formato  
Frustaci-2019-Future Oncol-VoR.pdf

Solo gestori archivio

Descrizione: Article
Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Licenza: Tutti i diritti riservati
Dimensione 2.29 MB
Formato Adobe PDF
2.29 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/408815
Citazioni
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 14
Social impact